Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer.
BACKGROUND
Typhlitis is being recognized with increasing frequency as a serious complication of aggressive chemotherapy for hematologic and solid malignancies.


METHODS
In this report the authors describe two cases of typhlitis in patients with metastatic breast cancer treated with taxol and doxorubicin.


RESULTS
Both cases occurred during the first cycle of treatment with taxol (180 mg/m2) and doxorubicin (75 mg/m2), being given simultaneously as 72-hour continuous intravenous infusions.


CONCLUSIONS
Two cases of typhlitis have occurred after combined treatment with taxol and doxorubicin, while typhlitis has not been described after treatment with either drug alone.
Pestalozzi
B C
BC
Medicine Branch, National Cancer Institute, Bethesda, MD 20892.
Sotos
G A
GA
Choyke
P L
PL
Fisherman
J S
JS
Cowan
K H
KH
O'Shaughnessy
J A
JA
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy / Q000378:metabolism; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000188:drug therapy / Q000378:metabolism; D002429:Cecal Diseases / Q000139:chemically induced*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D008207:Lymphatic Metastasis; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*
D004317:Doxorubicin; D017239:Paclitaxel